Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

7.0%

13 terminated/withdrawn out of 187 trials

Success Rate

86.6%

+0.1% vs industry average

Late-Stage Pipeline

13%

24 trials in Phase 3/4

Results Transparency

12%

10 of 84 completed trials have results

Key Signals

30 recruiting10 with results10 terminated

Enrollment Performance

Analytics

N/A

90(61.6%)

Phase 2

21(14.4%)

Phase 4

14(9.6%)

Phase 3

10(6.8%)

Phase 1

9(6.2%)

Early Phase 1

2(1.4%)

146Total

N/A(90)

Phase 2(21)

Phase 4(14)

Phase 3(10)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (187)

Showing 20 of 187 trials

NCT03363217Phase 2Active Not Recruiting

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Role: collaborator

NCT07534345Not ApplicableNot Yet Recruiting

Efficacy of Dry Needling in Reducing Pain During Sexual Intercourse

Role: collaborator

NCT07536906Not Yet Recruiting

Falls Validation Study

Role: collaborator

NCT04670016Completed

HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers

Role: collaborator

NCT07525856Not ApplicableNot Yet Recruiting

Acceptability of a Nurse-led Telehealth Remote Self-monitoring Model of Care in Patients With Rheumatoid Arthritis

Role: lead

NCT06817694Not ApplicableRecruiting

Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene

Role: lead

NCT04862260Early Phase 1Active Not Recruiting

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

Role: lead

NCT04171661Early Phase 1Active Not Recruiting

Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa

Role: lead

NCT07483658Not ApplicableNot Yet Recruiting

Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

Role: lead

NCT05402930Not ApplicableCompleted

Angiomammography and Neoadjuvant Chemotherapy

Role: lead

NCT05390229Completed

Screening Contrast-enhanced Mammography

Role: lead

NCT06276257Not ApplicableRecruiting

Paravertebral Block for Mastectomy With Immediate Reconstruction

Role: lead

NCT05176015Not ApplicableCompleted

Nystagmus Assessment for Patients Consulting in the Emergency Department for Acute Vertigo

Role: lead

NCT07193134Phase 1Recruiting

GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment

Role: lead

NCT06399822Not ApplicableRecruiting

Impact of Capillaroscopy on the Management of Undifferentiated Connective Tissue Disease

Role: lead

NCT06052683Not ApplicableRecruiting

A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer.

Role: lead

NCT05471479Phase 4Recruiting

Activated CHARcoal in Poisoned Patient - Pilot Trial

Role: collaborator

NCT06296173Not ApplicableRecruiting

Open Lung Protective Extubation Following General Anesthesia

Role: collaborator

NCT07275060Phase 4Active Not Recruiting

Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart

Role: collaborator

NCT07094048Phase 4Recruiting

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

Role: lead